Retrospective evaluation of the efficacy of daily paroxetine/tadalafil combination in patients with premature ejaculation and erectile dysfunction

OBJECTIVE: Premature ejacula-tion (PE) and erectile dysfunction (ED) are sexual dysfunction diseases affecting males. The phos-phodiesterase type 5 (PDE5) inhibitors such as tadalafil are used to treat ED whereas selective serotonin reuptake inhibitors (SSRIs) are pre-ferred for PE. Most of the patients with ED also suffer from PE simultaneously. The combined drug therapies are commonly preferred as they favor elevated intra-vaginal ejaculation latency time (IELT) scores and improved sexual function. The study aimed to evaluate the efficacy and safety of daily paroxetine and tadalafil combina-tion therapy in patients with PE and ED.PATIENTS AND METHODS: A total of 81 PE patients with ED were enrolled in the study. Patients were treated with daily paroxetine 20 mg and tadalafil 5 mg for 4 weeks. Pre-and post-treatment IELT, premature ejaculation pro-file (PEP), and International Index of Erectile Function-Erectile Function (IIEF-EF) scores of the patients were analyzed.RESULTS: The mean IELT and PEP index scores, and mean IIEF-EF values improved af -ter combination therapy (p<0.001 for each). When lifelong and acquired PE+ED patients were compared, significant improvements were observed in IELT, PEP, and IIEF-EF scores in both groups (p<0.001).CONCLUSIONS: Even though the treatment methods are different, combined therapies to treat simultaneous PE and ED presence are ef-fective compared to monotherapies. However, there is still no definitive treatment that can cure all subtypes of PE or ED.